KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.99

Efficacy and Safety of Oteseconazole in Severe Vulvovaginal Candidiasis Categorized by Candida Species and Previous Genital Tract Infection: A Post Hoc Analysis of a Phase 3 Trial.

Xiaoqian Wang, Fengxia Xue, Chunlian Zhang, Ruifang An, Hongjie Ruan, Liancheng Zhu, Liping Zhang, Qinping Liao

Drug Des Devel Ther 20 599356

PMID42266513
PMCIDPMC13245468
DOI10.2147/DDDT.S599356
发表日期2026-06-10
入排依据:记录类型属于综述、Meta 分析、社论、评论、病例或指南。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:森林图/亚组分析图;Figure 3:森林图/亚组分析图;Figure 4:森林图/亚组分析图。
摘要

摘要

PURPOSE: Oteseconazole, a novel selective fungal CYP51 inhibitor, demonstrated superior efficacy over fluconazole for severe vulvovaginal candidiasis (SVVC) in a phase 3 trial. However, whether the efficacy and safety of oteseconazole on SVVC varies by Candida species or previous genital tract infection remains unknown. PATIENTS AND METHODS: In this exploratory post hoc analysis of a phase 3 trial (NCT04956419), data were analyzed from patients with SVVC receiving oteseconazole (600 mg on day 1 and 450 mg on day 2) or fluconazole (150 mg on days 1 and 4). The primary outcome was therapeutic cure rate at day 28, assessed in subgroups categorized by Candida species (Candida albicans vs. non-Candida albicans) and previous genital tract infection (yes vs. no). RESULTS: Of 319 patients categorized by Candida species or previous genital tract infection (oteseconazole, n = 160; fluconazole, n = 159), 249 were in the Candida albicans subgroup and 70 in the non-Candida albicans subgroup. Regarding previous infection, 107 had previous genital tract infection, while 212 had none. At day 28, the therapeutic cure rates were higher with oteseconazole than with fluconazole across subgroups categorized by Candida species (Candida albicans: 76.56% vs 56.20%, propensity score [PS]-weighted odds ratio [OR] 2.59 [95% CI 1.76, 3.81]; non-Candida albicans: 28.13% vs 13.16%, PS-weighted OR 2.78 [95% CI 1.17, 6.64]) and previous genital tract infection (yes: 61.70% vs 45.00%, PS-weighted OR 2.03 [95% CI 1.18, 3.51]); no: 69.03% vs 46.46%, PS-weighted OR 2.59 [95% CI 1.74, 3.85]). Additionally, the incidence of treatment-emergent adverse events was comparable between oteseconazole and fluconazole across all subgroups. CONCLUSION: Oteseconazole may offer benefits and is generally well tolerated in patients with SVVC, irrespective of Candida species and previous genital tract infection. However, given the exploratory post hoc nature and the relatively small subgroup sample size, these findings warrant further validation in larger studies.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Forest plot for therapeutic cure, clinical cure, and mycological cure with oteseconazole versus fluconazole at day 28 ( A ) and day 14 ( B ) across subgroups categorized by Candida species.
非 KM Figure
Figure 2Mean change from baseline in composite VSS score over 28 days across subgroups categorized by Candida species.
非 KM Figure
Figure 3Forest plot for therapeutic cure, clinical cure, and mycological cure with oteseconazole versus fluconazole at day 28 ( A ) and day 14 ( B ) across subgroups categorized by previous genital tract infection.
非 KM Figure
Figure 4Mean change from baseline in composite VSS score over 28 days across subgroups categorized by previous genital tract infection.
非 KM Figure